It has been reported that targeting CXCR1 and CXCR2 using orally active small-molecule antagonist, SCH 527123, potentially inhibits human colon cancer liver metastasis (16) and also sensitizes cells to oxaliplatin (17). Here, CXCR2 is linked to colonic neoplasm.